Eli Lilly expanded muscle health research via a $650 million collaboration with Juvena Therapeutics, leveraging AI platforms to discover muscle regeneration candidates. Bristol Myers Squibb’s RayzeBio unit paid $350 million upfront for Philochem’s prostate cancer radiopharmaceutical OncoACP3. SpliceBio raised $135 million to advance ABCA4 gene therapy for Stargardt disease, reflecting strong investment trends in novel modalities. Nicoya Lifesciences acquired Applied Photophysics to bolster biologics characterization, illustrating ongoing commitment to enhancing drug discovery infrastructure.